

Title of Trial: A double-blind, randomized, placebo-controlled, parallel-group Phase II study to explore the potential beneficial effects of safinamide on cognition in non-demented patients with idiopathic Parkinson's disease (PD) and cognitive impairment.

Investigational Product: safinamide

Trial No.: EMR701165-024

Study Centers: Not available

Trial Initiation Date: 29 Nov 2010

Trial Completion Date: 05 Apr 2012

Development Phase: Phase 2

Publication (reference): None

Study Objectives: Data not available

Methodology: Data not available

Number of Subjects (Planned and Analyzed): Data not available

Diagnosis and Main Criteria for Inclusion/Exclusion: Data not available

Study Treatment: Data not available

Criteria for Evaluation: Data not available

Statistical Methods: Data not available

Results: Data not available

Conclusions: Data not available

Due diligence was done and all potential information sources have been exhausted. No source documents for this study were identified. Due to non-availability of clinical study reports and synopses, results were not posted in EudraCT database

Merck KGaA

These results are supplied for informational purposes only.